A case, and some pharmacological considerations. from the perspective of a virologist. Anna Maria Geretti University of Liverpool, United Kingdom
|
|
- Imogen Gardner
- 5 years ago
- Views:
Transcription
1 A case, and some pharmacological considerations. from the perspective of a virologist Anna Maria Geretti University of Liverpool, United Kingdom 1
2 Case History: Mr RS 53-year-old male Diagnosed HIV positive in 1999 Baseline CD4 count 46 cells Baseline viral load 83,000 cps Subtype C Past hepatitis B infection Hepatitis C negative Oct 1999 starts AZT/3TC + IDV
3 Medical and ART history Date started Date stopped ART Viral load CD4 Resistance Oct 1999 Oct 2000 AZT/3TC IDV Oct 2000 Nov 2001 ABC/3TC EFV 31, Nov 2001 Jul 2004 TDF d4t 3TC LPV/r < Jul 2004 Jul 2008 TDF ATV FPV/r Jul 2008 Nov 2011 TDF RAL DRV/r (600/100 bid) <50 to RT: 67N 215Y 184V 74V 100I 103N RT: None PR: 32I
4 Mr RS Which is your preferred strategy? 1. Do nothing as long as the viral load is <200 cps 2. Address patient-related psyco-social issues & adherence 3. Address sample- and/or lab-related technical issues 4. Request more tests which? 5. Change or intensify the ART regimen
5 Management strategies Review: Technical issues of viral load testing Adherence, tolerability, psycho-social issues Expected potency of the regimen Drug-drug interactions (DDIs) and food requirements Reasonable to perform a drug resistance test Reasonable to check drug levels CD4 nadir and pre-art viral load inform Size of HIV DNA reservoir Likelihood of compartmentalised virus replication
6 Plasma HIV-1 RNA during ART Spivak et al. Trends Mol Med 2016
7 HIV-1 DNA log 10 cps per 10 6 CD4 T-cells Cellular HIV-1 DNA load during suppressive ART Cohort started 2 NRTIs + EFV or NVP, achieved VL <50 cps within 6 months, and during subsequent follow-up had VL consistently <50 cps (no blips or interruptions) while remaining on the initial NNRTI (n=104) Years of suppressive ART Mean change integrated HIV-1 DNA for 10 yrs of ART (log 10 cps/10 6 PBMC) +0.2 [95% CI -0.2, +0.6; p 0.28] Geretti et al. Int. Workshop HIV & Hepatitis Viruses Drug Resistance 2013; Ruggiero et al. EBioMed 2015
8 Virus replication in sanctuary compartments due to poor drug penetration or activity Virus reactivation in latently infected cells, with presence of ART ensuring that new cells cannot be productively infected
9 Untimed drug levels & resistance test at LLV predict viral load rebound >1000 cps First LLV plasma sample: PI/NNRTI concentration and resistance test (n=328) Concentrations classed as therapeutic' or suboptimal' based on target C trough Genotypic sensitivity score (GSS) of regimen by Stanford algorithm Independent predictors of VL rebound >1000 cps (adjor) o Suboptimal drug levels = 2.53 (95% CI ; p<0.001) o GSS <3 = 1.55 (95% CI ; p=0.04) o LLV (cps): = 2.48 (95% CI ) = 2.36 (95% CI ) = 3.65 (95% CI )(p<0.001) Gonzalez-Serna et al. CROI 2015
10 Low drug levels predict faster resistance Gonzalez-Serna et al. CROI 2015
11 Case History: Mr RS DRV plasma concentration in range Plasma resistance test (RT, PR, IN) wild-type X 3 CSF HIV RNA 3128 cps/ml CSF resistance test RT: 67N 215Y 184V 100I 103N PR: wild-type IN: RT 155H
12 HIV-1 RNA Detection in CSF according to LLV HIV-1 RNA measured in paired plasma and CSF of 43 subjects with plasma VL <50 cps over 12 months of ART and in 40 subjects with a history of LLV HIV-1 RNA detected in CSF in 0/43 vs. 9/40 (22%) respectively Detection of HIV-1 RNA in CSF associated with low nadir CD4 count (p=0.030) and black heterosexual exposure group (p=0.007) but not with drug concentration or CPE score Nightingale et al. J NeuroVirol 2016
13 HIV-1 RNA cps/ml SAILING Case-1 ART-experienced, INI-naïve TDF FTC + DTG 50 mg OD PDVF Wk cps/ml Confirm Wk cps/ml 386 cps/ml INI mutation PDVF= Protocol-defined virological failure; FC = Fold change; RC = Replication capacity Day 1 PDVF Confirm. HIV-1 RNA A49G, S230R, R263K A49G, S230R, R263K DTG FC RAL FC INI RC 20% 7.1% 12% No NRTI resistance at any time point Underwood et al. European HIV & Hepatitis Workshop 2015
14 HIV-1 RNA cps/ml SAILING Case-2 ART-experienced, INI-naïve ABC 3TC + DTG 50 mg OD PDVF Wk cps/ml Confirm Wk 108 retest 407 cps/ml 1000 Day 1 PDVF Week HIV-1 RNA IN mutation - N155H DTG FC RAL FC IN RC NR b NR PDVF BR: No emergent resistance, loss of M184M/V PDVF= Protocol-defined virological failure; FC = Fold change; RC = Replication capacity Underwood et al. European HIV & Hepatitis Workshop 2015
15 You plan to modify the ART regimen Which is your preferred strategy? 1. DRV/b + DTG 2. DRV/b + DTG + ETR 3. DRV/b + DTG + MVC 4. DRV/b + MVC + ETR 5. DRV/b + DTG + MVC + ETR Add TDF or TAF to any of the above, +/- FTC? Which dose of DTG?
16 Pharmacology of integrase inhibitors Dose DTG EVG RAL 50mg od (50-100mg bd) 150mg od (boosted) 400mg bd Potent inhibitors of integrase enzyme Protein binding-adjusted IC90/95 values in the low ng/ml range - High inhibitory quotient (IQ) - DTG > EVG > RAL Each INI has unique PK/PD properties PK variability highest for RAL and lowest for DTG
17 Pharmacology of integrase inhibitors Different hepatic metabolism: RAL and DTG minimal cytochrome P450 (CYP) involvement; EVG primarily thorugh CYP3A4 RAL and DTG have minimal DDI profiles EVG requires boosting to be amenable to OD dosing and has greater DDI potential manageable as with RTV Podany et al. 2016
18 Pharmacology of integrase inhibitors Dose DTG EVG RAL 50mg od (bd if INI experienced) 150mg od (boosted) 400mg bd Food effect on drug exposure Take with food if possibility of INI resistance Take with food Take without regard to food Low ( 33%), moderate ( 41%), and high ( 33%) fat meals increased AUC Light ( 36%), and high ( 91%) fat meals increased AUC High fat doubles AUC, food increases variability Absorption affected by divalent / trivalent cations, such as those found in multivitamins and antacids
19 DTG mean plasma concentration (ng/ml) Effect of food on DTG exposure - healthy volunteers Fasting Low fat Moderate fat High fat 500 PA-IC µg/ml *50 mg formulation Time (hours) Low, moderate, and high fat meals increase DTG AUC by 33%, 41%, and 66%, respectively. In INI-naive patients, dose with or without food. In INI-resistant patients, dose with food. Song et al. Antimicrob Agents Chemother 2012
20 INI chelation with cations Mean DTG concentration (µg/ml) Al/Mg containing antacid taken together Antacid +/- 2h after EVG 74% 26% Dolutegravir alone Dolutegravir +antacid Dolutegravir + antacid 2h later Time (hrs) EVG AUC Decreased 45% EVG C min Decreased 41% Binding of integrase inhibitors Mg 2+ Mg 2+ Patel et al. JAC 2011; Pommier et al. Nat Rev 2005; Stribild SmPC June 23rd 2015; Tivicay SmPc Oct 1st 2015 Mg Mg Not recommended RAL Separate DTG and EVG/c
21 Impact of acid-reducing agents and multivitamins on DTG exposure Co-administered drug DTG C or C 24 Geometric mean change Recommendation Antacids and supplements Magnesium / aluminiumcontaining antacid AUC* 74% Calcium supplements 39% Iron supplements 56% Multivitamins 32% Acid-lowering agents Take antacids and supplements a minimum of 2 hours after or 6 hours before DTG 1 Omeprazole 5% No significant effect observed 2 C : Trough concentration 1. Tivicay SmPC January Patel et al. J Antimicrob Chemother 2011
22 Pharmacology of integrase inhibitors Dose DTG EVG RAL 50mg od (bd if INI experienced) 150mg od (boosted) 400mg bd Food effect Take with food if possibility of INI resistance Low ( 33%), moderate ( 41%), and high ( 33%) fat meals increased AUC Take with food Light ( 36%), and high ( 91%) fat meals increased AUC Take without regard to food High fat doubles AUC, food increases variability Metabolism UGT1A1 (CYP3A 10-15%) CYP3A / UGT1A1/3 UGT1A1 Protein binding >99% 99% 76-83% Half life 11-12h 9h 9h Dose-exposure Dose proportional Less than Nearly up to 100mg dose-proportional dose-proportional
23 DTG distribution and CSF penetration Plasma protein binding: >99% 1 Blood:plasma ratio: minimal association with blood cellular components 1 A Phase IIIb study assessed the distribution of DTG in CSF 2 DTG concentrations observed in CSF at both Week 2 and Week 16 averaged 18 ng/ml (comparable to unbound concentration) and exceeded the in vitro IC 50 against wildtype viruses (0.2 ng/ml) 2 for all subjects, suggesting that DTG was able to achieve therapeutic concentrations in the CSF 1. Tivicay SmPC, January 2014; 2. Letendre et al. CROI 2013
24 Special groups Swallowing DTG EVG RAL Granule being developed ( bioavailability) Cannot be chewed or crushed Chewable tablets, granules ( bioavailability) Children Not licensed <12y Not licensed <18y, avoid <6y Pregnancy No data FDA Cat B Limited data FDA Cat B Licensed from 4 weeks Some data FDA Cat C Renal impairment No adjustment DTG exposure reduced in severe renal disease FDC with TDF not <70, stop <50 FDC with TAF >30 No adjustment Cirrhosis CP-A No adjustment No adjustment No adjustment CP C Caution Not recommended Caution
25 Mean DTG concentration (µg/ml) Dose-exposure relationship for DTG DTG PK parameters at Week 2 by dose in the SPRING-1 Phase IIb trial 1, mg QD 2 25 mg QD 2 50 mg QD 2 QD dose C max (μg/ml) AUC 0 (µg h/ml) C (µg/ml) IQ mg 1, (37) 16.0 (40) 0.30 (71) PA-IC µg/ml* 25 mg 1, (43) 23.1 (48) 0.54 (67) mg 1, (27) 48.1 (40) 1.20 (62) 19 Values shown are geometric means (CV%) Post-dose time (hours) DTG shows low to moderate PK variability 1,2 All drug levels well above the in-vitro PA-IC 90 of μg/ml 1,2 *PA-IC 90 is the protein-adjusted 90% inhibitory concentration Inhibitory quotient is defined as C /PA IC van Lunzen et al. Lancet Infect Dis 2012; 2. Rockstroh et al. HIV
26 Responders, % SAILING: Response rates by quartile of DTG c 0_avg SAILING: Phase III study in ART-experienced, INI-naïve subjects 100 Responders Non-responders μg/ml ( ) Response rate 63.5% μg/ml ( ) Response rate 72.9% C 0_avg quartile μg/ml ( ) Response rate 82.4% μg/ml ( ) Response rate 75.3% The average plasma concentration of DTG was a significant predictor of virological response: subjects in the lowest quartile had a lower response Song et al. ICAAC 2013
27 DDI liability DTG EVG RAL Metabolism UGT1A1 (CYP3A 10-15%) CYP3A UGT1A1/3 UGT1A1 Perpetrator of DDIs No effect on CYPs, UGTs. Inhibits OCT2 Cobicistat potent CYP3A, mod CYP2D6 and MATE1 EVG mod inducer of CYP2C9 No effect on CYPs, UGT or PgP Divalent cations Al/Mg/Ca/Fe/Multivit amins Separate -6 or +2h Al/Mg antacids ±2h Multivitamins ±4h Al/ Mg contraindicated Ca: not clinically meaningful Gastric ph No significant interaction No significant interaction RAL absorption with OMP ( 39%) / FAM ( 45%); no adjustment needed
28 DTG interactions Oral contraceptives 1 Commonly used medications H 2 -receptor antagonists (e.g.,ranitidine, cimetidine) 2 Prednisone 1, Methadone 1, Rifabutin 1 Metformin 1 Interactions No dose adjustment necessary No dose adjustment necessary No dose adjustment necessary Limit the total daily dose of metformin to 1,000 mg. When stopping DTG, the metformin dose may require an adjustment. Monitoring of blood glucose when initiating concomitant use and after withdrawal of DTG recommended Multivitamins, calcium supplements, iron supplements 1 DTG to be administered 2 hours before or 6 hours after taking these agents Magnesium/aluminium-containing antacids 1 DTG to be administered 2 hours before or 6 hours after taking these agents Carbamazepine, rifampicin, efavirenz; nevirapine and tipranavir/r 1 The recommended dose of DTG is 50 mg twice daily when co-administered with these agents. In the presence of INI resistance, combination with these agents should be avoided Note: Co-administration of dofetilide and dolutegravir is contraindicated. 1,2 1. TIVICAY Summary of Product Characteristics. September TRIUMEQ Summary of Product Characteristics. September 2015
29 Impact of ARVs on DTG exposure Co-administered drug DTG C or C 24 Geometric mean change Recommendation 1 Protease inhibitors DRV/r 600/100 mg BID* 38% No DTG dose adjustment required ATV 400 mg OD* 180% No DTG dose adjustment required ATV/r 300/100 mg OD* 121% No DTG dose adjustment required NNRTIs RPV 25 mg OD 22% No DTG dose adjustment required EFV 600 mg OD 75% DTG 50 mg BID should be given ETR 200 mg BD 88% DTG should not be given with ETR without co-administration of ATV/r, DRV/r or LPV/r NRTIs TDF 300 mg OD 8% No DTG dose adjustment required C : Trough concentration *DTG 30 mg OD studied; Unboosted ATV is not licensed in the EU; INInaive patients; alternative combinations should be considered where possible for INI-experienced patients with certain INI-associated resistance substitutions or clinically suspected INI resistance 1.Tivicay SmPC January 2014
30 DTG with ETR DTG + ETR without bpi DTG + ETR with bpi twice daily DTG 50mg qd + LPVr 400/100 bd DTG AUC + ETR 200mg bd DTG AUC 70% + DRVr 600/100 bd DTG AUC 25% Song et al. AAC 2011
31 VIIV EUROPEAN SCIENTIFIC REVIEW FORUM ON DOLUTEGRAVIR
32 ETR + MVC = MVC (600mg or 150 bd without/with PI/b) RTV + MVC = MVC (150mg bd) RTV + DTG = potentially DTG ETR + DTG = DTG
33 You plan to modify the ART regimen Which is your preferred strategy? 1. DRV/b + DTG 2. DRV/b + DTG + ETR 3. DRV/b + DTG + MVC 4. DRV/b + MVC + ETR 5. DRV/b + DTG + MVC + ETR Added TAF/FTC DTG 100mg bd
34 Thanks to Saye Khoo (UoL) David Back (UoL) Romina Quercia (ViiV) 34
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationClinical Pharmacology of Integrase Inhibitors
Clinical Pharmacology of Integrase Inhibitors Dr Marta Boffito MD PhD Head of Clinical Trials, St Stephen Centre (SSAT) Consultant Physician, Chelsea and Westminster Foundation Trust Reader, Imperial College
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationSELECTING THE BEST ART FOR EACH PATIENT
SELECTING THE BEST ART FOR EACH PATIENT Corklin R Steinhart, MD, PhD Head, Global Medical Directors ViiV Healthcare CNVX/HIVP/0025/16 5th Asian Conference on Hepatitis & AIDS 第五届亚洲肝炎与艾滋病学术会议 28-29 May
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationIvy Song, 1 Kimberly Adkison, 2 Mark Lovern 3, Joannellyn Chiu 3, Jenny Huang 1, Cindy Vavro 1, Mounir Ait-Khaled 1, Brian Wynne 1 and Sherene Min 1
Pharmacokinetic-Pharmacodynamic Modeling & Simulation of the Virologic Response of Dolutegravir in HIV-Infected Patients with Integrase Inhibitor Resistant Virus Ivy Song, 1 Kimberly Adkison, 2 Mark Lovern
More informationThe Pharmacology of Integrase Inhibitors. Marta Boffito Chelsea and Westminster Hospital, London Imperial College, London
The Pharmacology of Integrase Inhibitors Marta Boffito Chelsea and Westminster Hospital, London Imperial College, London Currently available integrase inhibitors Raltegravir (approved 10/2007) Elvitegravir*
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationThird Agent Advantages Disadvantages. Component Tenofovir/emtricitabine (TDF/FTC) 300/200 mg (coformulated with EFV as Atripla) 1 tab once daily
Table I. Recommended and Alternative Antiretroviral Regimens (DHHS Guidelines, May 1, 2014) Recommended Regimens Nucleoside Analog Reverse Transcriptase Inhibitor (NRTI) Third Agent Advantages Disadvantages
More informationPharmacologic Characteristics and Delivery Options for Integrase Inhibitors
Pharmacologic Characteristics and Delivery Options for Integrase Inhibitors Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationFirst line ART Rilpirivine A New NNRTI. Chris Jack Physician, Durdoc Centre ethekwini
First line ART Rilpirivine A New NNRTI Chris Jack Physician, Durdoc Centre ethekwini Overview: Rilpirivine an option for ARV Naïve patients History Current guidelines Efficacy and Safety Tolerability /
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationHIV Virology & Resistance
Themes Viral load Tropism Drug resistance HIV Virology & Resistance Anna Maria Geretti Institute of Infection & Global Health The HIV Virology Timeline HIV-1 isolated HIV replicates at high levels throughout
More informationProfessor Anna Maria Geretti
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Professor Anna Maria Geretti Institute of Infection & Global Health, University of Liverpool 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationAntiretroviral Drugs
Antiretroviral Drugs Dr Paddy Mallon UCD HIV Molecular Research Group Associate Dean for Research and Innovation UCD School of Medicine and Medical Science paddy.mallon@ucd.ie UCD School of Medicine &
More informationAntiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationTRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA
TRIUMEQ * (DTG/ABC/3TC): BIOEQUIVALENCE DATA *In studies supporting TRIUMEQ, DTG 50 mg + ABC 600 mg/3tc 300 mg were used. Bioequivalence has been demonstrated. DTG, dolutegravir; ABC, abacavir; 3TC, lamivudine
More informationCNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz
CNS Toxicity of Integrase Inhibitors Myth or Reality? Ignacio Pérez Valero Unidad de VIH. Hospital U. La Paz Question for the audience Do you think that any integrase inhibitor drug produce CNS adverse
More information2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?
Switching from old regimens David Nolan Department of Immunology, Royal Perth Hospital, Western Australia Institute for Immunology and Infectious Diseases, Murdoch University, Western Australia What is
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
Antiretroviral Medications: What you need to know Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Associate Professor, Department of Pharmacy Practice Jefferson College of Pharmacy, Thomas Jefferson University
More informationJuluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW
Juluca (dolutegravir, rilpivirine) NEW PRODUCT SLIDESHOW Introduction Brand name: Juluca Generic name: Dolutegravir, rilpivirine Pharmacological class: HIV-1 integrase strand transfer inhibitor (INSTI)
More informationClinical Pharmacology Related Considerations.
Clinical Pharmacology Related Considerations. David Back University of Liverpool UK David Back University of Liverpool Disclosures Honoraria received for advisory boards and lectures from AbbVie, BMS,
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationNew HIV EACS and Italian Guidelines
Original Article HIV correlated pathologies and other infections Marco Borderi New HIV EACS and Italian Guidelines Infectious Disease Unit - S. Orsola-Hospital - University of Bologna Corresponding author:
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationClinical Management of Resistance. AMJ Wensing, MD, PhD
Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationCurrent Drugs: Drug-Drug Interactions
Slide 1 Current Drugs: Drug-Drug Interactions David Back University of Liverpool UK David Back University of Liverpool May 2013 Toxicity HCV med Comed Reduced Efficacy The major effect of DAAs is to increase
More informationClinical considerations in switching antiretroviral therapy
Clinical considerations in switching antiretroviral therapy David Jilich Department of Infctious Diseases, 1st Faculty of Medicine, Charles University in Prague and Na Bulovce Hospital 4th CEE Meeting
More information2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall
2nd line failure, provincial evaluation process for 3rd line therapy, 3rd line treatment options James Nuttall Paediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University
More informationExisting and most needed paediatric ARV formulations
Existing and most needed paediatric ARV formulations Martina Penazzato Paediatric HIV advisor WHO HIV Department, Geneva Mach 7th 2016 Paediatric coverage still lags behind 45 40 35 30 25 20 15 10 5 0
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationv Dr Anton Pozniak Chelsea and Westminster Hospital, London Injectable ARVs a S.W.O.T Analysis
18 th Annual Resistance and Antiviral Therapy Meeting v Dr Anton Pozniak Chelsea and Westminster Hospital, London Thursday 18 September 2014, Royal College of Physicians, London Injectable ARVs a S.W.O.T
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin
Pharmacokinetics and Drug Interaction Profile of Cobicistat boosted-elvitegravir with Atazanavir, Rosuvastatin or Rifabutin S Ramanathan, H Wang, T Stondell, A Cheng, and BP Kearney Gilead Sciences, Inc.,
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationHIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract. Sandrine LEFEUVRE, Julie BOIS-MAUBLANC, Camélia GUBAVU,
More informationDDIs, INSTIs, TB and Hepatitis
DDIs, INSTIs, TB and Hepatitis David Back University of Liverpool UK David Back University of Liverpool Rio de Janeiro August 2018 Disclosures Honoraria received for advisory boards and lectures from AbbVie,
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationDolutegravir: Pros and Cons (Are There Any Cons?)
Mountain West AIDS Education and Training Center Dolutegravir: Pros and Cons (Are There Any Cons?) Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, MW AETC
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationSTRIBILD (aka. The Quad Pill)
NORTHWEST AIDS EDUCATION AND TRAINING CENTER STRIBILD (aka. The Quad Pill) Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor of Medicine, University of Washington Presentation prepared
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationA clinical guide to managing drugdrug interactions in antiretroviral therapy
HIVPA 2008, 6 th June 2008 HIV Pharmacology and TDM B Marta Boffito MD PhD St. Stephen s Centre Chelsea and Westminster Hospital, London A clinical guide to managing drugdrug interactions in antiretroviral
More informationINDUCTION/MAINTENANCE Clinical Case
INDUCTION/MAINTENANCE Clinical Case Dr. Jose R Arribas @jrarribas INDUCTION/MAINTENANCE (more or less) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationPolypharmacy and Drug-Drug Interactions
Polypharmacy and Drug-Drug Interactions David Back University of Liverpool UK David Back November 2016 Disclosures Honoraria received for advisory boards and lectures from AbbVie, BMS, Gilead, Merck, ViiV,
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationHIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
More information13 th Conference on Retroviruses and Opportunistic Infections (CROI)
REPORT FROM 13 th Conference on Retroviruses and Opportunistic Infections (CROI) February 5 8, 5 2006 Denver, CO 1 Tipranavir Significantly Reduces Concentrations of Other ARVs -10 % change PK -30-50 -70-68
More informationHIV - Therapy Principles
HIV - Therapy Principles Manuel Battegay and Christine Katlama Basel, Switzerland and Paris, France Disclosure MB has received honoraria for advisory board participation from Gilead, MSD, Pfizer, ViiV
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationImproving PI drug resistance scores. Jens Verheyen, MD Institute of Virology University Duisburg-Essen
Improving PI drug resistance scores Jens Verheyen, MD Institute of Virology University Duisburg-Essen Overview Why can all PI drug resistance scores be improved? Do we still need to improve PI drug resistance
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationEfavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST. Graeme Meintjes University of Cape Town
Efavirenz vs dolutegravir for 1st line ART: Is it time to change? The argument AGAINST Graeme Meintjes University of Cape Town Benefits of dolutegravir Superior efficacy in SINGLE trial Side effect profile
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationPaediatric Infectious Diseases Unit, Red Cross War Memorial Children s Hospital & University of Cape Town
A Public Sector Antiretroviral Treatment Programme for Treatment-Experienced Children and Adolescents in the Western Cape Province of South Africa Using Darunavir/Ritonavir-, Raltegravir- and Etravirine-Containing
More information